Taiwan vaccine maker plans to conduct Phase 3 clinical trial in Europe

Taiwan-based vaccine maker Medigen will conduct a Phase 3 clinical trial for its COVID-19 vaccine in Europe once it has received approval from European authorities, which would help pave the way for its entry into European and other international markets, the company announced Wednesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)